Narasimhan’s poor decision making has had negative consequences not just for Novartis but also for the industry and patients. Let’s hope it’s not repeated.
Novartis Delayed Reveal Of Bad Data For $2.1 Million Gene Therapy. Now Patients And Pharma Suffer.
